PT  - JOURNAL ARTICLE
AU  - TAKAO MATSUBARA
AU  - KATSUYUKI KUSUZAKI
AU  - AKIHIKO MATSUMINE
AU  - HARUHIKO SATONAKA
AU  - KEN SHINTANI
AU  - TOMOKI NAKAMURA
AU  - ATSUMASA UCHIDA
TI  - Methylene Blue in Place of Acridine Orange as a Photosensitizer in Photodynamic Therapy of Osteosarcoma
DP  - 2008 May 01
TA  - In Vivo
PG  - 297--303
VI  - 22
IP  - 3
4099  - http://iv.iiarjournals.org/content/22/3/297.short
4100  - http://iv.iiarjournals.org/content/22/3/297.full
SO  - In Vivo2008 May 01; 22
AB  - We recently established a unique therapeutic modality for musculoskeletal sarcomas, combining acridine orange (AO) with photodynamic surgery (PDS), photodynamic therapy (PDT) and radiodynamic therapy (RDT); excellent results were obtained in the inhibition of local tumor recurrence after intralesional excision. However, AO is not yet approved for clinical use and intravenous injection. Therefore, methylene blue (MB), which has a very similar chemical structure to AO and is already in clinical use for other diseases, was investigated. In vitro studies using mouse osteosarcoma (LM8) cells revealed that MB-PDT had a strong cytocidal effect and that MB was not radiosensitive, showing no effect in RDT. In vivo studies showed that MB did not specifically accumulate in mouse osteosarcoma tissue and that it did not inhibit tumor growth. MB is not a better photosensitizer than AO in PDS, PDT and RDT for osteosarcoma.